India’s drug regulator CDSCO has approved Ozempic (semaglutide) for adults with type-2 diabetes. The once-weekly injectable, developed by Novo Nordisk, helps control blood sugar and supports weight loss. While effective, it carries risks like nausea, pancreatitis, and gallbladder issues. Pricing in India is expected between INR 17,000 to INR 26,000 per month.